

# SARCODO - Evaluation of coagulopathy and endothelial dysfunction as a predictive factor for the severity of SARS-CoV-2/COVID-19 infection

Head :SMADJA David, UMR-S1140 and Biosurgical Research Laboratory (Carpentier Foundation)

Last update : 05/05/2021 | Version : 1 | ID : 73746

## General

### Identification

Detailed name Evaluation of coagulopathy and endothelial dysfunction as a predictive factor for the severity of SARS-CoV-2/COVID-19 infection

Sign or acronym SARCODO

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CPP2020-04-048b

### General Aspects

Medical area Biology  
Hematology  
Infectious diseases

Study in connection with Covid-19 Yes

Keywords von Willebrand factor, endothelium, COVID-19, haemostasis

### Scientific investigator(s) (Contact)

Name of the director SMADJA

Surname David

Address HEGP, Service d'hématologie, 20 rue Leblanc, 75015 Paris

Phone 33613838972

Email david.smadja@aphp.fr

Unit UMR-S1140 and Biosurgical Research Laboratory (Carpentier Foundation)

Organization Inserm

## Collaborations

## Funding

Funding status Public

Details ANR SARCODO (France Foundation)

## Governance of the database

Sponsor(s) or organisation(s) responsible AP-HP

Organisation status Public

Presence of scientific or steering committees No

## Additional contact

Email yannick.vacher@aphp.fr

## Main features

## Type of database

Type of database Others

Specify Clinical and laboratory database

Database recruitment is carried out as part of an interventional study No

## Database objective

Main objective Study the coagulopathy, vascular lesion and markers for tissue distress to characterise the exacerbation of patients with COVID-19 and identify patient populations who will develop or experience exacerbation of a thromboembolic or microvascular process, but also require curative anticoagulation.

Inclusion criteria Patients aged at least 18 years  
Hospitalised in an intensive care or medicine department for suspected COVID-19.  
Patients covered by a social security regime (other than the state welfare scheme)  
Patient having been informed of the study and having given their informed consent in writing, or

for whom a family member/trusted person has given their agreement

## Population type

Age  
Adolescence (13 to 18 years)  
Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered                      General population

## Pathology

Gender                                      Male  
    Woman

Geography area                          Regional

French regions covered by the database      Île-de-France

Detail of the geography area            HEGP and Cochin Hospital

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY)      2020

### Size of the database

Size of the database (number of individuals)      [1000-10 000[ individuals

Details of the number of individuals              1000

### Data

Type of data collected                      Clinical data  
    Biological data

Clinical data (detail)                          Direct physical measures  
    Medical registration

Presence of a biobank                      Yes

Contents of biobank                          Whole blood

Plasma  
Blood cells isolated  
DNA

## Procedures

Followed pathology

## Promotion and access

### Promotion

Link to the document	<a href="#">2020- Debuc et al- SCRR Covid19.pdf</a>
Link to the document	<a href="#">2020- Smadja_Article_Angiopoietin-Covid19-Angiogenesis.pdf</a>
Link to the document	<a href="#">2020- diehl et al- AIC-covid19.pdf</a>
Link to the document	<a href="#">2020- Khider et al-CEC JTH.pdf</a>
Link to the document	<a href="#">2020- Petrazzuolo et al- Oncoimmunology COVID FRP.pdf</a>
Link to the document	<a href="#">2020- bastard et al- Science AutomAb IFN Covid.pdf</a>
Link to the document	<a href="#">2021- Philippe_et_al-Angiogenesis-WILLEBRAND.pdf</a>
Link to the document	<a href="#">2021- Planquette et al- TR- EP Covid.pdf</a>
Link to the document	<a href="#">2020- Guerin et al- SCRR- Article_MultidimensionalProteomicAppro.pdf</a>
Link to the document	<a href="#">2020- Goudot et al- tropo covid-Front Med.pdf</a>

### Access